These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9715505)

  • 1. The International Life Sciences Institute's role in the evaluation of alternative methodologies for the assessment of carcinogenic risk.
    Robinson D
    Toxicol Pathol; 1998; 26(4):474-5. PubMed ID: 9715505
    [No Abstract]   [Full Text] [Related]  

  • 2. Panel discussion on the application of alternative models to cancer risk assessment.
    Pettit SD
    Toxicol Pathol; 2001; 29 Suppl():191-5. PubMed ID: 11695557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. International Life Sciences Institute.
    Robinson DE; MacDonald JS
    Toxicol Pathol; 2001; 29 Suppl():13-9. PubMed ID: 11695549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A perspective on current and future uses of alternative models for carcinogenicity testing.
    Goodman JI
    Toxicol Pathol; 2001; 29 Suppl():173-6. PubMed ID: 11695554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Committee on Carcinogenicity of Chemicals in Food, Consumer Products and theEnvironment. Statement on ILSI/HESI research programme on alternative cancer models.
    Blain PG
    Toxicol Pathol; 2003; 31(2):254-7. PubMed ID: 12696588
    [No Abstract]   [Full Text] [Related]  

  • 6. Criteria for the evaluation of studies in transgenic models.
    Popp JA
    Toxicol Pathol; 2001; 29 Suppl():20-3. PubMed ID: 11695558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of human cancer risk: challenges for alternative approaches.
    Omenn GS
    Toxicol Pathol; 2001; 29 Suppl():5-12. PubMed ID: 11695561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transgenic assays and the identification of carcinogens.
    Tennant R; Haseman J; Stoll RE
    Environ Mol Mutagen; 2001; 37(1):86-92. PubMed ID: 11170246
    [No Abstract]   [Full Text] [Related]  

  • 9. CB6F1-rasH2 mouse: overview of available data.
    Usui T; Mutai M; Hisada S; Takoaka M; Soper KA; McCullough B; Alden C
    Toxicol Pathol; 2001; 29 Suppl():90-108. PubMed ID: 11695565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The in vivo rodent test systems for assessment of carcinogenic potential.
    van der Laan JW; Spindler P
    Regul Toxicol Pharmacol; 2002 Feb; 35(1):122-5. PubMed ID: 11846641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of the uses of rats and mice for assessing carcinogenic risk from chemicals in humans.
    Ward JM
    Asian Pac J Cancer Prev; 2010; 11(1):18. PubMed ID: 20593921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transgenic mouse models for the identification of human carcinogens: a European perspective.
    van Kreijl CF; van Steeg H
    Toxicol Pathol; 1998; 26(6):757-8. PubMed ID: 9864092
    [No Abstract]   [Full Text] [Related]  

  • 13. Alternative models for carcinogenicity testing.
    Cohen SM; Robinson D; MacDonald J
    Toxicol Sci; 2001 Nov; 64(1):14-9. PubMed ID: 11606797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neonatal mouse assay for tumorigenicity: alternative to the chronic rodent bioassay.
    Flammang TJ; Tungeln LS; Kadlubar FF; Fu PP
    Regul Toxicol Pharmacol; 1997 Oct; 26(2):230-40. PubMed ID: 9356286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of DNA repair-deficient XPA transgenic mice in short-term carcinogenicity testing.
    van Steeg H; Klein H; Beems RB; van Kreijl CF
    Toxicol Pathol; 1998; 26(6):742-9. PubMed ID: 9864090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P53+/- hemizygous knockout mouse: overview of available data.
    Storer RD; French JE; Haseman J; Hajian G; LeGrand EK; Long GG; Mixson LA; Ochoa R; Sagartz JE; Soper KA
    Toxicol Pathol; 2001; 29 Suppl():30-50. PubMed ID: 11695560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative models for carcinogenicity testing: weight of evidence evaluations across models.
    Cohen SM
    Toxicol Pathol; 2001; 29 Suppl():183-90. PubMed ID: 11695556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carcinogenicity evaluation: comparison of tumor data from dual control groups in the CD-1 mouse.
    Baldrick P; Reeve L
    Toxicol Pathol; 2007 Jun; 35(4):562-9. PubMed ID: 17562489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI.
    MacDonald J; French JE; Gerson RJ; Goodman J; Inoue T; Jacobs A; Kasper P; Keller D; Lavin A; Long G; McCullough B; Sistare FD; Storer R; van der Laan JW
    Toxicol Sci; 2004 Feb; 77(2):188-94. PubMed ID: 14657512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mouse-specific carcinogens: an assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice.
    Battershill JM; Fielder RJ
    Hum Exp Toxicol; 1998 Apr; 17(4):193-205. PubMed ID: 9617631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.